|| Print ||
|Sunday, February 01, 2009|
In the race to cure malaria, the devastating disease that claims 1 million lives each year, every development is critical. The deadliest strain has grown increasingly resistant to chloroquine, the safest and cheapest anti-malarial drug available. The parasite that carries the virus has developed a “siphon” to purge the drug from itself. But instead of developing a new drug, a lengthy and costly process, Portland State University professor David Peyton and his research team at DesignMedix are re-engineering the original. These “reversed chloroquines” block the parasite’s siphon, killing the parasite. Some of these molecules are 10 times more effective than chloroquine alone, decreasing the required dosage significantly. Smaller doses could mean fewer side effects and lower manufacturing costs, Peyton says. The drug is expected to move to human trials in the next two to three years. Peyton sees the eradication of the disease as critical to the health of women and children, and for the health of malaria-stricken countries. “What the world needs now,” Peyton says, “is very good, very safe, very cheap anti-malarial drugs.”
Monday, July 14, 2014
BY VIVIAN MCINERNY | OB BLOGGER
Some people think Amazon’s winking eye logo is starting to look like a hoodwink.
Wednesday, August 27, 2014
BY JESSICA RIDGWAY
How State Representative Julie Parrish (House District 37) balances life between work and play.
Monday, August 18, 2014
Portland is in the middle of another construction boom, with residential and office projects springing up downtown, in the Pearl and Old Town. OB Web Editor Jessica Ridgway documents the new wave.
Tuesday, August 26, 2014
Strong public schools shore up the economy, survey respondents say. But local schools demonstrate lackluster performance.
Tuesday, July 08, 2014
BY LINDA BAKER | OB EDITOR
The New Yorker recently published a sharply worded critique of “disruptive innovation,” one of the most widely cited theories in the business world today. The article raises questions about the descriptive value of disruption and innovation — whether the terms are mere buzzwords or actually explain today's extraordinarily complex and fast changing business environment.
Update: We caught up with Portland's Thomas Thurston, who shared his data driven take on the disruption controversy.
Thursday, July 24, 2014
BY CLIFF HOCKLEY | OB GUEST CONTRIBUTOR
With the increasing retirements of Baby Boomers, a massive real estate shift has created a significant increase in demand for NNN properties. The result? Increased demand has triggered higher prices and lower yields.
Wednesday, August 06, 2014
BY LINDA BAKER | OB EDITOR
Portland startup Green Endeavor strikes gold, inking a partnership with Underwriters Laboratories, an Illinois-based consulting and certification company with offices in 46 countries.
|The Private 150: Bigger But Leaner|
|The Perfect Food|
|Powerlist: Staffing Firms|
|Taxis Uber Alles?|
|Halliburton to pay $1.1B to settle lawsuits|
|U.S. eating habits improve, except among poor|
|Google tests drone deliveries|
|Abercrombie to remove logos from most clothing|
|FBI investigates JPMorgan 'cyber-attack'|
|GoPro launches camera dog harnesses|
|Snapchat now worth $10B|
How six leading foundations are working together for a better Oregon.
Vigilant enters a New Year with a new president.
How George Fox has become one of Oregon's largest private universities.
Lane Powell Shareholder William T. Patton has been appointed to the board of directors for Cascade AIDS Project, an organization that provides educational services and outreach to thousands of Oregonians living with HIV/AIDS.
Fifty-one Lane Powell lawyers were recently selected by their peers for inclusion in The Best Lawyers in America® (Best Lawyers) 2015; of those selected, 23 lawyers are from the Firm’s office in Portland, Oregon.
Barran Liebman is proud to announce that Andrew Schpak, a Partner of the firm, has been named Chair of the American Bar Association’s Young Lawyers Division for the 2014-2015 bar year.